Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) EBITDA (2022 - 2026)

Sagimet Biosciences' EBITDA history spans 5 years, with the latest figure at -$10.8 million for Q1 2026.

  • Quarterly EBITDA rose 41.14% to -$10.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$43.6 million through Mar 2026, up 23.46% year-over-year, with the annual reading at -$51.1 million for FY2025, 12.74% down from the prior year.
  • EBITDA came in at -$10.8 million for Q1 2026, down from -$9.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$6.4 million in Q3 2023 to a low of -$18.3 million in Q1 2025.
  • The 5-year median for EBITDA is -$8.1 million (2023), against an average of -$9.8 million.
  • The largest YoY upside for EBITDA was 41.72% in 2025 against a maximum downside of 174.88% in 2025.
  • Sagimet Biosciences' EBITDA stood at -$7.1 million in 2022, then fell by 14.11% to -$8.1 million in 2023, then tumbled by 102.09% to -$16.4 million in 2024, then skyrocketed by 41.72% to -$9.6 million in 2025, then dropped by 12.51% to -$10.8 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's EBITDA are -$10.8 million (Q1 2026), -$9.6 million (Q4 2025), and -$12.9 million (Q3 2025).